BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250303
DTEND;VALUE=DATE:20250307
DTSTAMP:20260515T112602
CREATED:20241128T113542Z
LAST-MODIFIED:20241128T113542Z
UID:40201-1740960000-1741305599@www.pharmajournalist.com
SUMMARY:15th World ADC London Summit 2025
DESCRIPTION:Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval\, the field has seen a surge in multi-billion-dollar acquisitions\, commercialisation deals\, and licensing agreements. These developments have enabled the ADC community to make strides in bringing these therapies to earlier-line treatments and expand their use to wider patient populations. \nReturning for its 15th anniversary year\, World ADC London is the leading European conference uniting over 1000 ADC enthusiasts to maximise the therapeutic index of ADCs. Whether you are brand new to the field or have over a decade of experience\, work in discovery or manufacturing\, hold a strategic position or work day-to-day in the lab\, this meeting offers something for you! \nTake a look at the full agenda here. \nEmbark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation\, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle. \nHere are some of the leading minds sharing translatable lessons to advance your pipeline including: \n\nAlireza Tafazzol\, Senior Scientist II\, Oncology Bioinformatics\, AbbVie.\nOsama Chahrour\, Principal Scientist\, Chemical Development\, AstraZeneca.\nYu-Shin Hsu\, Research Analyst\, Independent.\nJinwon Jung\, Senior Director\, Protein Engineering\, ABL Bio.\nHayley Jackman\, Director\, CMC Regulatory Affairs\, AstraZeneca.\nLolke de Haan\, Vice President\, Toxicology\, ADC Therapeutics.\nMax Lee\, Associate Director\, AstraZeneca.\nPaul WolstenholmeHogg\, Vice President\, Medicinal Chemistry\, ADC Therapeutics.\nTomohiro Fujii\, ADC Researcher\, Ajinomoto Bio-Pharma Services.\nYing Buechler\, Chief Technology Officer\, Ambrx\, a Johnson & Johnson Company.\nPaul Jaminet\, Chief Executive Officer\, Angiex.\nUchechukwu OkorjiObike\, Senior Scientist\, Bioassay Development\, AstraZeneca.\n\nSee the full speaker faculty and session details here. \nDon’t miss this chance to unlock unmissable R&D\, focused industry networking opportunities\, and emerging trends taking hold of the ADC field with sessions from 120+ world-leading speakers including Daiichi Sankyo\, AstraZeneca\, Pfizer\, AbbVie\, Merck\, GSK\, Johnson & Johnson\, ADC Therapeutics and more.
URL:http://www.pharmajournalist.com/event/15th-world-adc-london-summit-2025/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
END:VCALENDAR